A bivalent CMV vaccine formulated with human compatible TLR9 agonist CpG1018 elicits potent cellular and humoral immunity in HLA expressing mice

Vijayendra Dasari; Kirrilee Beckett; Shane Horsefield; George Ambalathingal; Rajiv Khanna

doi:10.1371/journal.ppat.1010403

Loading metrics

Open Access

Peer-reviewed

Research Article

A bivalent CMV vaccine formulated with human compatible TLR9 agonist CpG1018 elicits potent cellular and humoral immunity in HLA expressing mice

Vijayendra Dasari ,

Roles Conceptualization, Data curation, Formal analysis, Methodology, Writing – original draft, Writing – review & editing

* E-mail: Vijayendra.Dasari@qimrberghofer.edu.au (VD); rajiv.khanna@qimrberghofer.edu.au (RK)

Affiliation QIMR Berghofer Centre for Immunotherapy and Vaccine Development and Tumour Immunology Laboratory, Department of Immunology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
⨯
Kirrilee Beckett,

Roles Data curation, Formal analysis, Methodology, Writing – review & editing

Affiliation QIMR Berghofer Centre for Immunotherapy and Vaccine Development and Tumour Immunology Laboratory, Department of Immunology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
⨯
Shane Horsefield,

Roles Data curation, Formal analysis, Methodology, Writing – original draft, Writing – review & editing

Affiliation QIMR Berghofer Centre for Immunotherapy and Vaccine Development and Tumour Immunology Laboratory, Department of Immunology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
⨯
George Ambalathingal,

Roles Data curation, Formal analysis, Methodology, Writing – review & editing

Affiliation QIMR Berghofer Centre for Immunotherapy and Vaccine Development and Tumour Immunology Laboratory, Department of Immunology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
⨯
Rajiv Khanna

Roles Conceptualization, Formal analysis, Funding acquisition, Project administration, Supervision, Writing – original draft, Writing – review & editing

* E-mail: Vijayendra.Dasari@qimrberghofer.edu.au (VD); rajiv.khanna@qimrberghofer.edu.au (RK)

Affiliation QIMR Berghofer Centre for Immunotherapy and Vaccine Development and Tumour Immunology Laboratory, Department of Immunology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia

https://orcid.org/0000-0003-2241-0353

⨯

A bivalent CMV vaccine formulated with human compatible TLR9 agonist CpG1018 elicits potent cellular and humoral immunity in HLA expressing mice

Vijayendra Dasari,
Kirrilee Beckett,
Shane Horsefield,
George Ambalathingal,
Rajiv Khanna

Published: June 23, 2022
https://doi.org/10.1371/journal.ppat.1010403

Reader Comments (0)

Post a new comment on this article

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

T cells
Is the Subject Area "T cells" applicable to this article?

Thanks for your feedback.
Cytotoxic T cells
Is the Subject Area "Cytotoxic T cells" applicable to this article?

Thanks for your feedback.
Antibodies
Is the Subject Area "Antibodies" applicable to this article?

Thanks for your feedback.
Vaccines
Is the Subject Area "Vaccines" applicable to this article?

Thanks for your feedback.
Immune response
Is the Subject Area "Immune response" applicable to this article?

Thanks for your feedback.
Enzyme-linked immunoassays
Is the Subject Area "Enzyme-linked immunoassays" applicable to this article?

Thanks for your feedback.
Antibody response
Is the Subject Area "Antibody response" applicable to this article?

Thanks for your feedback.
Booster doses
Is the Subject Area "Booster doses" applicable to this article?

Thanks for your feedback.